Description

This episode questions whether assigning the label “ACLF” to a deteriorating patient truly alters clinical decisions, or if focusing on the specifics of organ failure and reversibility is more useful. Experts debate the real-world utility of prognostic scores, the clarity (or confusion) created by multiple definitions, and whether the ACLF concept drives urgency, facilitates transplant access, or improves outcomes. A thought-provoking look at where terminology meets bedside care.

Moderator: Tom Marjot 

Speakers: Paolo Angeli and Julia Wendon

This EASL Studio is supported by GENFIT. The EASL Studio has received no input from GENFIT with regards to the content of this programme.